# Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Study · id `cardio:ct-nct06499857` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06499857](<https://clinicaltrials.gov/study/NCT06499857>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06499857

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT06499857. Randomized; triple masking; primary purpose treatment. Start 2025-04-14 (actual); primary completion 2027-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT06499857, source copy `cardio:ctgov-nct06499857-2025-11-14`, retrieved 2026-10-26)
- Started: 2025-04-14 (actual) (ClinicalTrials.gov record NCT06499857, source copy `cardio:ctgov-nct06499857-2025-11-14`, retrieved 2026-10-26)
- Primary completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT06499857, source copy `cardio:ctgov-nct06499857-2025-11-14`, retrieved 2026-10-26)
- Completion: 2028-06 (anticipated) (ClinicalTrials.gov record NCT06499857, source copy `cardio:ctgov-nct06499857-2025-11-14`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06499857, source copy `cardio:ctgov-nct06499857-2025-11-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06499857-2025-11-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
- Acronym: SEMINAL-AF
- Condition: Overweight or Obesity
- Condition: Atrial Fibrillation
- Intervention (Drug): Semaglutide
- Intervention (Drug): Placebo
- Lead sponsor: University of Chicago
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: University of Chicago (`cardio:org-university-of-chicago`)

## Provenance

Content hash: 618b3f32eb170f1f5b6534a36e91fccac1b92e5807db13a9aa9f5064937c7626
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
